Prometheus Biosciences is a biotechnology company developing a precision medicine approach to the discovery, development, and commercialization of therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting with inflammatory bowel disease. Co. utilizes its proprietary precision medicine platform, Prometheus360, which includes a gastrointestinal bioinformatics database and sample biobank, to identify therapeutic targets and develop therapeutic candidates to engage those targets. In parallel, Co. is developing companion diagnostic tests designed to identify patients more likely to respond to our therapeutic candidates. The RXDX stock yearly return is shown above.
The yearly return on the RXDX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the RXDX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|